Proteomic analysis of the postsynaptic density implicates synaptic function and energy pathways in bipolar disorder. by Föcking, Melanie et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
Psychiatry Articles Department of Psychiatry
29-11-2016
Proteomic analysis of the postsynaptic density
implicates synaptic function and energy pathways
in bipolar disorder.
Melanie Föcking
Royal College of Surgeons in Ireland, mfocking@rcsi.ie
Patrick Dicker
Royal College of Surgeons in Ireland, patdicker@rcsi.ie
Lorna M. Lopez
Royal College of Surgeons in Ireland, lornalopez@rcsi.ie
Mafdalena Hryniewiecka
Royal College of Surgeons in Ireland, magdalenahryniewieck@rcsi.ie
K Wynne
University College Dublin
See next page for additional authors
This Article is brought to you for free and open access by the Department
of Psychiatry at e-publications@RCSI. It has been accepted for inclusion in
Psychiatry Articles by an authorized administrator of e-
publications@RCSI. For more information, please contact epubs@rcsi.ie.
Citation
Föcking M, Dicker P, Lopez LM, Hryniewiecka M, Wynne K, English JA, Cagney G, Cotter DR. Proteomic analysis of the
postsynaptic density implicates synaptic function and energy pathways in bipolar disorder. Translational Psychiatry. 2016;6(11):e959
Authors
Melanie Föcking, Patrick Dicker, Lorna M. Lopez, Mafdalena Hryniewiecka, K Wynne, Jane A. English, G
Cagney, and David R. Cotter
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/psychart/45
— Use Licence —
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/psychart/45
OPEN
ORIGINAL ARTICLE
Proteomic analysis of the postsynaptic density implicates
synaptic function and energy pathways in bipolar disorder
M Föcking1, P Dicker2, LM Lopez1, M Hryniewiecka1, K Wynne3, JA English1, G Cagney3 and DR Cotter1,4
The postsynaptic density (PSD) contains a complex set of proteins of known relevance to neuropsychiatric disorders such as
schizophrenia and bipolar disorder. We enriched for this anatomical structure in the anterior cingulate cortex of 16 bipolar disorder
samples and 20 controls from the Stanley Medical Research Institute. Unbiased shotgun proteomics incorporating label-free
quantitation was used to identify differentially expressed proteins. Quantitative investigation of the PSD identiﬁed 2033 proteins,
among which 288 were found to be differentially expressed. Validation of expression changes of DNM1, DTNA, NDUFV2, SEPT11
and SSBP was performed by western blotting. Bioinformatics analysis of the differentially expressed proteins implicated metabolic
pathways including mitochondrial function, the tricarboxylic acid cycle, oxidative phosphorylation, protein translation and calcium
signaling. The data implicate PSD-associated proteins, and speciﬁcally mitochondrial function in bipolar disorder. They relate
synaptic function in bipolar disorder and the energy pathways that underpin it. Overall, our ﬁndings add to a growing literature
linking the PSD and mitochondrial function in psychiatric disorders generally, and suggest that mitochondrial function associated
with the PSD is particularly important in bipolar disorder.
Translational Psychiatry (2016) 6, e959; doi:10.1038/tp.2016.224; published online 29 November 2016
INTRODUCTION
The postsynaptic density (PSD) is a highly organized structure
attached to the postsynaptic neuronal terminal. It comprises a
complex network of cytoskeletal scaffolding and signaling
proteins that facilitate the movement of receptor and signaling
complexes. The PSD is critical for normal neurotransmission and
synaptic plasticity1 through the modulation of signaling mechan-
isms involving N-methyl-D-aspartate, α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid and metabotropic glutamate receptors.
Synaptic plasticity is implicated in neuropsychiatric disorders,2–5
and thus the PSD is implicated.6–13 However, although known
constituents of the PSD have been implicated in bipolar disorder
and schizophrenia at both gene14–16 and protein expression
levels,14,17–20 no major ﬁndings are reported to contribute to
bipolar disorder risk.21,22 As synaptic plasticity is highly dependent
on mitochondrial function,23 energy metabolism acting at the
level of the PSD may underpin PSD dysfunction in bipolar disorder
and indeed other neuropsychiatric disorders.
Mass spectrometry-based proteomic methods have the ability
to reliably identify and quantify several thousands of disease-
associated protein changes derived from complex anatomical
structures. The reliable quantitation of low-abundance proteins
within speciﬁc cellular compartments until recently has been
challenging and this has led to a shift in the use of pre-
fractionation enrichment methods combined with mass
spectrometry-based proteomic techniques. This approach has
successfully yielded a detailed characterization of the PSD
proteome in rodents and in healthy postmortem human brain
tissue.24 The differential expression of the PSD in schizophrenia
compared with controls was ﬁrst reported recently by our team25
highlighting altered pathways of endocytosis, long-term potentia-
tion and calcium signaling in schizophrenia. The identiﬁed PSD
proteome (including a gene critical to synaptic plasticity—MAPK3)
was signiﬁcantly associated in gene set enrichment analysis with
schizophrenia, validating independent reports of PSD enrichment
in schizophrenia. Furthermore, numerous mitochondrial proteins
were differentially expressed in the PSD schizophrenia proteome
and these changes were not associated with antipsychotic
administration.25 This was in keeping with previous studies of
the brain in neuropsychiatric diseases.26–36 These ﬁndings are of
relevance to bipolar disorder, considering the known overlap with
schizophrenia in terms of clinical presentation, genomic, structural
imaging,37 transcriptome and protein expression.26 To date, no
study has assessed the protein expression of the PSD in the cortex
in bipolar disorder compared with controls.
In the current investigations, we enriched for the PSD in the
anterior cingulate cortex (ACC) in bipolar disorder and in control
human brain samples. This is a candidate brain region in both
bipolar disorder and schizophrenia.38–41 We undertook a label-free
liquid chromatography–mass spectrometry (LC-MS/MS) investiga-
tion to identify disease-associated changes in protein expression
within the PSD in bipolar disorder compared with controls. We
hypothesized three ﬁndings. First, that the altered protein
expression would overlap with that observed in schizophrenia
PSD.25 Second, that a distinct pattern of altered protein expression
would emerge in keeping with genomic and mRNA expression
bipolar disorder studies. Third, that mitochondria-associated
proteins would be differentially expressed in this PSD-enriched
fraction in bipolar disorder (based on our own and other recent
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studies implicating mitochondrial function in major psychiatric
disorders).
MATERIALS AND METHODS
Samples
Human postmortem brain tissue of the supragenual (BA24) ACC was
obtained from the Stanley Medical Research Institute’s Array Collection
(www.stanleyresearch.org). The series consists of 105 subjects, including 35
schizophrenia, 35 bipolar disorder and 35 control cases. Information on
prescribed psychotropic medication is provided by the Stanley Medical
Research Institute.
A subset of 20 bipolar disorder samples and 20 control samples were
selected from the series to match as closely as possible for age and tissue
pH.35,42 Table 1 provides detailed demographic information on these
subjects. To obtain enough tissue for the enrichment protocol, two
samples were subpooled based on the Euclidean distance (Supplementary
Table 1). Investigators were blind to group identity until completion of the
data analysis. Ethical approval (Application No. REC080) was granted by the
Royal College of Surgeons in Ireland Research Ethics Committee. Two
subpooled samples were subsequently excluded from the bipolar disorder
group as we were unable to obtain enough PSD protein for our analyses.
Comparing the PSD in ACC in bipolar disorder and controls
The enrichment for the PSD was undertaken using methods established
previously and recently validated for postmortem brain material.24 In brief,
the method involves differential sucrose centrifugation and further
fractionations by Triton X-100 extraction ﬁrst at pH 6, and then at pH 8,
leading to the separation of the PSD fraction (for details see
Supplementary Methods and our previous work25).
Sample preparation for mass spectrometry
Fifty micrograms of protein from each homogenate was denatured in 10 μl
2% RapiGest solution (Waters, Elstree, UK) at 80 °C for 10min. Samples were
subsequently reduced in the presence of 50mM TCEP (tris2-carboxyethyl-
phosphine) (Sigma Aldrich, Wicklow, Ireland) at 60 °C for 60 minutes and
alkylated in the dark with 200mM iodoacetic acid acid (Sigma Aldrich).
Protein was digested with 5 μg of sequence grade modiﬁed trypsin
(Promega, Southampton, UK), in a 37 °C shaking incubator for 16 hours.
Digestion was stopped and the RapiGest precipitated with formic acid
(0.1% v/v). After digestion, peptides were resuspended in 0.5% triﬂuor-
oacetic acid, dried in an Eppendorf Vacufuge (Eppendorf, Hauppauge, NY,
USA) and desalted using ZipTips (Millipore, Bedford, MA, USA).
Mass spectrometry analysis
Label free LC-MS was performed on a Thermo Scientiﬁc Q Exactive mass
spectrometer connected to a Dionex Ultimate 3000 (RSLCnano) chromato-
graphy system. Tryptic peptides were resuspended in 0.1% formic acid.
Each sample was loaded onto a fused silica emitter (75 μm ID, pulled using
a laser puller (Sutter Instruments P2000)), packed with Reprocil Pur C18
(1.9 μm) reverse phase media and was separated by an increasing
acetonitrile gradient over 120 minutes at a ﬂow rate of 250 nL/min. The
mass spectrometer was operated in positive ion mode with a capillary
temperature of 320 °C, and with a potential of 2300V applied to the frit. All
data was acquired with the mass spectrometer operating in automatic data
dependent switching mode. A high resolution (70,000) MS scan (300–1600
m/z) was performed using the Q Exactive to select the 12 most intense
ions prior to MS/MS analysis using HCD.
Data processing and analysis
We collected two types of mass spectrometry data in the experiments. It is
formally a ‘shotgun’ experiment and the collected tandem mass spectra
were used to identify the proteins. The parent ion signal (MS1 scan) on
high resolution instruments such as the Q Exactive used is widely used to
calculate protein abundance in so-called ‘label-free’ proteomics
experiments.43 The signal for each peptide derived from a given protein
is integrated over time (the time it takes to enter the instrument via HPLC),
and the summed signals are used to estimate the relative abundance of
each protein. To analyze the data, we used the MaxQuant programme
speciﬁcally for label-free experiments using high resolution instruments
supported by Andromeda as a database search engine for peptide
identiﬁcation.44 This program has several statistical control steps to ensure
that only high quality reliable ion signals are accepted.
Label free quantitation (LFQ) was performed as previously described.45
Carbamidomethylation was deﬁned as a ﬁxed modiﬁcation, while
oxidation and acetylation of the protein N-terminus were deﬁned as
variable modiﬁcations. Only peptides with seven or more amino acid
residues were allowed for identiﬁcation. Additionally, at least one unique
peptide was required to identify a protein. The cut off for false discovery
rate for peptide and protein identiﬁcation was set to 0.01. The label free
algorithm takes the maximum number of identiﬁed peptides between any
two samples and compares the intensity of these peptides to determine
peptide ratios.
LFQ intensity values were used for protein quantiﬁcation across the
groups.
Raw LFQ intensities were extracted from the MaxQuant software and log
base 2 transformed prior to analysis to eliminate distributional skew and to
give approximate normality. To avoid bias associated with protein under-
representation between groups, proteins were excluded in cases where
there was less than 50% availability of the LFQ intensities in each biological
group. After data ﬁltering, 45872 LFQ values remained. Regression
normalization was performed to remove technical variation between
samples.46
Statistical analysis
Protein intensities were screened for anomalous and missing data before
log transformation (log base 2) and quantile regression normalization. A
two-sample t-test (two-sided) analysis was performed on each protein
comparing bipolar disorder with controls.
Signiﬁcance testing was performed at the 5% level, and a false discovery
rate (FDR)47 of 5% was used to ﬂag those protein identiﬁcations deemed
statistically signiﬁcant after adjustment for multiple comparisons. Fold
changes were obtained from an exponentiation (power of 2) of the
Table 1. Demographic information for the 36 samples used for
analyzing protein expression by LC-MS/MS in the anterior cingulate
cortex
Control Bipolar disorder
Number 20 16
Race 20 White 15 White
1 Black
Sex 15 M, 5 F 10 M, 6 F
Side of brain 11 Right, 9 left 8 Right, 8 left
Psychotic features No 9 Yes, 5 no, 2 unclear
Cause of death 18 Cardiac
2 Other medical
4 Cardiac
7 Other medical
5 Suicide
Mean age and range (y) 43.6 (31–57) 46.6 (19–64)
Mean PMI and range (h) 21 (9–31) 25.8 (12–38)
Mean brain pH and range 6.59 (6.0–6.94) 6.46 (5.97–6.97)
Mean RI and range (h) 2.9 (0–7) 4.9 (1–10)a
Mean lifetime alcohol
abuse (1= low, 5=high)
0.55 (0–3) 2.87 (0–5)
Smoking at time of death 3 Yes 7 Yes
5 No 3 No
12 Unknown 6 Unknown
Mean lifetime drug abuse
(1= low, 5=high)
0.2 (0–1) 2.06 (0–5)
Prescribed psychotropic medication use at time of death, no. of on/no. of
off
Antipsychotics 0/20 6/10
Antidepressants 0/20 7/9
Mood stabilizers 0/20 11/5
Abbreviations: F, female; LC-MS/MS, liquid chromatography–mass spectro-
metry; M, male; PMI, postmortem interval; RI, refrigerator interval; y, years.
For alcohol and drug use, a categorical scale was employed: 0= little or
none, 1= social use, 2=moderate past use, 3=moderate present use,
4=heavy past use and 5=heavy present use. aSigniﬁcantly different
(Po0.05) from controls following independent t-test (disease versus
control).
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difference in group means. Fold changes o1 were inverted (−1/fold
change) to present a consistent scale of measurement.
Family-wise analysis was performed for two families of proteins.
Mitochondrial dysfunction and the septin family were investigated as
they were highlighted from pathway analysis and visual inspection,
respectively. A family-wise P-value for the difference between groups was
obtained from a nested model (analysis of variance) of the corresponding
proteins (n= 39 mitochondrial dysfunction, n= 9 septins).
The management of data and statistical analyses were carried out with
the SAS version 9.2 statistical software (SAS Institute, Cary, NC, USA) and R
version 3.1 statistical software (R Foundation for Statistical Computing,
Vienna, Austria).
Classiﬁcation of ﬁndings
See Supplementary Methods for methods of classiﬁcation of protein
changes using DAVID NIH, Search Tool for the Retrieval of Interacting
Genes and Ingenuity Pathway Analysis.
Validation of differentially expressed proteins
Proteins were selected for validation based on their degree of differential
expression and membership of the main processes and protein families
implicated by our current proteomic analysis and comparison with gene
expression literature,29,48 namely mitochondrial function (NDUFV2 and
SSBP), endocytosis (DNM1 and DTNA) and a member of the Septin family
Table 2. Top ﬁve signiﬁcant canonical pathways identiﬁed among the 288 differentially expressed proteins (t-test; Po0.007) between bipolar
disorder and control samples
Canonical pathway Proteins P-value Ratio
Oxidative phosphorylation ATP5A1, ATP5B, ATP5C1, ATP5F1, ATP5H, ATP5J2, ATP5O, CYC1, CYCS, MT-ND4, MT-ND5,
NDUFA2, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFA9, NDUFA10, NDUFA12, NDUFA13,
NDUFB1, NDUFB3, NDUFB4, NDUFB9, NDUFB11, NDUFS1, NDUFS2, NDUFS3, NDUFS5,
NDUFS6, NDUFV1, NDUFV2, UQCR10, UQCRC2, UQCRH, UQCRQ
1.06E− 39 36/109 (0.33)
Mitochondrial dysfunction ATP5A1, ATP5B, ATP5C1, ATP5F1, ATP5H, ATP5J2, ATP5O, CYC1, CYCS, GPD2, GPX4, MT-
ND4, MT-ND5, NDUFA2, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFA9, NDUFA10,
NDUFA12, NDUFA13, NDUFB1, NDUFB3, NDUFB4, NDUFB9, NDUFB11, NDUFS1, NDUFS2,
NDUFS3, NDUFS5, NDUFS6, NDUFV1, NDUFV2, PDHA1, PRDX3, UQCR10, UQCRC2, UQCRH,
UQCRQ
2.57E− 37 40/171 (0.234)
EIF2 signaling EIF2B3, EIF2S3, EIF3C, EIF4G2, PDPK1, PPP1CB, PPP1CC, RPL3, RPL6, RPL7, RPL8, RPL9,
RPL12, RPL18, RPL13A, RPS2, RPS5, RPS10
1.62E− 10 18/185 (0.097)
Calcium signaling ATP2A2, ATP2B2, CAMK2B, CAMKK1, ITPR1 LETM1, PPP3CA, PPP3R1, PRKACB, PRKAR2B,
RYR2, SLC8A2, TPM1, TPM3
2.64E− 07 14/178 (0.079)
TCA cycle CS, DLD, DLST, IDH3B, IDH3G, MDH2 6.36E− 07 6/23 (0.26)
Pathways were identiﬁed using Ingenuity Pathway Analysis (Qiagen, Redwood City, CA, USA). Signiﬁcant pathways are determined using the Fisher's exact test
to compare the number of proteins that are most signiﬁcantly perturbed in the data.
Figure 1. Forest plots of pathway analysis ﬁndings. The top ﬁve signiﬁcant canonical pathways identiﬁed among the false discovery rate (FDR)-
positive 288 differentially expressed proteins between bipolar disorder and control samples with fold changes and 95% conﬁdence intervals
are presented.
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Figure 2. Validation of differentially expressed proteins. Protein expression changes were determined in the 18 subpooled cases of the Stanley
Medical Research Institute Array Collection using western blot analysis. Representative images and the means of three independent
experiments are presented. Error bars indicate s.d. Western blots were prepared using lysates of subpools of anterior cingulate cortex samples
from patients with bipolar disorder (BD or BPD) and control subjects (C). Immunoblots were incubated with antibodies that speciﬁcally
recognize Dynamin (DNM1) at 120 kDa, Dystrobrevin (DTNA) at 84 kDa, Septin 11 (SEPT11) at 50 kDa, (NDUFV2) at 24 kDa, single-stranded
DNA-binding protein (SSBP) at 17 kDa and ERK2, used as a loading control, at 42 kDa. The images show a typical blot and the corresponding
graphs represent the signal intensity of the designated antibody measured by densitometry and corrected by the signal intensity of ERK2. The
mean of three independent experiments is presented. Error bars indicate s.d. ERK2 showed no signiﬁcant differences between disease and
control (P= 0.66). *Po0.05, ***Po0.001. In keeping with our liquid chromatography–mass spectrometry (LC-MS/MS) experiments, DNM1 and
DTNA1 expression levels were reduced and SEPT11 and NDUF2 were found to be increased. For DNM1, bipolar disorder cases showed two
bands, indicating potential post-translational modiﬁcations of the protein. However, we measured the band at 120 kDa for consistency. SSBP
was found to be decreased in the MS data but increased by western blotting. This most probably is due to the antibody recognizing different/
all isoforms of the protein.
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(SEPT11). Validation was undertaken using antibodies to these proteins in
the same above-mentioned bipolar disorder and control samples from the
Stanley Foundation Array series and animal model of haloperidol-treated
rats. For further details on the procedure and speciﬁcity of the antibodies
used for this study see Supplementary Methods.
RESULTS
Identiﬁcation of PSD proteins and pathways dysregulated in
schizophrenia
Thirty-six subjects pooled into 18 samples (8 pairs bipolar disorder
and 10 pairs of control) were studied (Table 1). A total of 2867
proteins were identiﬁed by tandem mass spectrometry (Q-
Exactive) after data input to the MaxQuant bioinformatics software
(Max-Planck Institute for Biochemistry, Munich, Germany). Proteins
were excluded if they were detected in less than 50% of samples
from each group, leaving 2033 proteins for inclusion in the ﬁnal
statistical analysis (Supplementary Table 2).
Six hundred twenty proteins were differentially expressed in
bipolar disorder compared with controls (P⩽ 0.05). Two hundred
eighty-eight proteins were found to be signiﬁcantly differentially
expressed after correcting for multiple testing with FDRo0.05
(Supplementary Table 2 and Supplementary Figure 1).
We asked whether the 288 PSD proteins contained functionally
related protein subsets. Five pathways were found to be
signiﬁcantly enriched when analyzed by Ingenuity Pathway
Analysis: oxidative phosphorylation, mitochondrial dysfunction,
EIF2 signaling, calcium signaling and the TCA cycle (Table 2 and
Figure 1).
Furthermore, both the septin and mitochondrial dysfunction set
of proteins were differentially expressed in a family-wise analysis
(both P-values o0.0001). The overall fold change for the nine
septins in the data set was 1.60, with a 95% conﬁdence interval
from 1.34 to 1.92. The 39 mitochondrial dysfunction proteins
showed an overall fold change of 2.05 (95% conﬁdence interval
1.57–2.67).
Conﬁrmation of proteomic ﬁndings
Validation using human samples. Validation was undertaken for
proteins from different classes, namely mitochondrial function,
endocytosis and septin family using western blotting for DNM1,
DTNA, NDUFV2, SSBP1 and SEPT11 in the PSD-enriched samples
from the Stanley Foundation Array series. See Figure 2 and Table 3
for the details of this validation work.
Validation using Haloperidol-treated rats. We previously explored
the proteomic effect of antipsychotic medication (haloperidol) on
the PSD using a rat model of antipsychotic drug treatment.25 Of
the 26 proteins in the treatment group found to be statistically
differentially expressed compared with controls, four were
included in our list of signiﬁcantly differentially expressed protein
in the bipolar disorder PSD (Po0.05; FAM162A, MCCC1, RIN1 and
mTOR), and one in our list of 288 FDR-corrected proteins in the
bipolar disorder PSD (FAM162A), and also altered in the same
direction. These ﬁndings suggest that differential expression of
these proteins may be drug-related. However, new western blot
analyses for the ﬁndings in this study demonstrated that DNM1,
DTNA, NDUFV2, SEPT11 and SSBP1 were not signiﬁcantly altered
in rats treated with haloperidol (Table 3), indicating that the
differential expression of these latter proteins in bipolar disorder
PSD is not antipsychotic treatment-related. Overall, as the majority
of expression changes observed by us in human samples were not
seen in the rat antipsychotic model, a purely pharmacological
explanation for the majority ﬁndings seems less likely (albeit using
a different species, and a single antipsychotic compound).
Comparison with schizophrenia PSD ﬁndings
We compared the above ﬁndings with the previous data obtained
from the schizophrenia PSD samples25 (LTQ ORBITRAP, see
Supplementary Tables 3 and 4 for details of overlapping proteins
and pathways). Taking all 143 differentially expressed schizo-
phrenia PSD proteins into consideration (Po0.05), we found an
overlap of 54.5% with the current bipolar PSD differentially
expressed data set (78/143), indicating a shared pathophysiology
in keeping with past genetic and proteomic49 investigations.
Mitochondrial ﬁndings using MitoCarta
As proteins linked to ‘mitochondrial dysfunction’ were prominent
in the list of differentially expressed proteins in the current study,
we asked whether the set of 288 proteins were more likely to have
a mitochondrial location in the cell.
Using MitoCarta (www.broadinstitute.org/pubs/MitoCarta/)50
we found 97 of the 288 differentially expressed proteins (FDR)
as having a mitochondrial localization (Supplementary Table 5).
There was an over-representation of mitochondrial proteins
differentially expressed within the PSD proteome of bipolar
disorder compared with controls (according to MitoCarta,
Po0.01 Fisher’s Exact test). As a group, mitochondrial proteins
were generally upregulated (Figure 1 and Supplementary Table 5
(83/97)). Overexpression of the mitochondrial-associated protein
NDUFV2 was conﬁrmed by western blotting (see validation work).
Table 3. Summary of validation work
Protein Id Protein name LC-MS/MS Validation (western blots) Rodent western blots (P-value)
Direction P-value Direction P-value
1740 DNM1 − 0.0006 − 0.039 0.731
787 DTNA − 0.013 − 0.029 0.86
319 NDUFV2 + 0.0037 + 5.6 × 10− 6 0.55
282 SEPT11 + 0.0004 + 2.46 × 10−7 0.715
347 SSBP − 0.0006 + 0.019 0.703
2415 GAD67 − 0.03 − 0.1 0.714
Abbreviations: LC-MS/MS, liquid chromatography–mass spectrometry; PSD, postsynaptic density. Validation was undertaken using western blot analysis for
DNM1, DTNA, NDUFV2, SEPT11 and SSBP1 in the PSD-enriched samples from the Stanley Foundation Array series. In keeping with our LC-MS/MS experiments,
DNM1 and DTNA1 expression was reduced, and SEPT11 and NDUF2 were found to be increased. SSBP was found to be decreased in the MS data but increased
by western blotting. This most probably is due to the antibody recognizing different/all isoforms of the protein. Western blot analyses demonstrated that
DNM1, DTNA, NDUFV2, SEPT11 and SSBP1 were not signiﬁcantly altered in rats treated with haloperidol.
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DISCUSSION
In this work, we used proteomic methods to study the PSD in
bipolar disorder. We provide robust data implicating this multi-
protein complex in bipolar disorder. Speciﬁcally, we enriched for
the PSD of the ACC in bipolar disorder and control samples and
used mass spectrometry-based proteomic methods to character-
ize differential expression of the PSD-associated proteins. Overall,
288 proteins were found to be signiﬁcantly differently expressed
following FDR out of a total of 2033 protein identiﬁed and suitable
for group comparison. The most notable proteomic changes
involved those proteins with roles in mitochondrial functions and
tricarboxylic acid cycle, oxidative phosphorylation and the
processes of protein translation through EIF2 signaling, long-
term potentiation, calcium signaling and endocytosis. All of these
processes are important in synaptic plasticity. Together, these
ﬁndings provide support for the view that abnormal protein
expression within the PSD contributes to the pathophysiology of
bipolar disorder through effects on synaptic plasticity.
The potential biological importance of the PSD to neuropsy-
chiatric illness is high. The PSD is an electron-dense multiprotein
complex under the postsynaptic membrane, which is readily
identiﬁed by electron microscopy. It has been characterized
previously in the rodent and human cortex using proteomic
methods, and it contains many neuroreceptors such as N-methyl-
D-aspartate, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid and metabotropic glutamate receptors, which inﬂuence
long-term potentiation51 and synaptic plasticity, and which are
implicated schizophrenia and bipolar disorder. In keeping with our
current data, previous studies characterizing the PSD have shown
that in addition to numerous neuroreceptors it contains many
proteins associated with mitochondrial function, protein transla-
tion, long-term potentiation, calcium signaling and endocytosis.
The PSD role in synaptic neurotransmission thus extends beyond
structural components of receptor signaling into roles in which
synaptic function is dependent such as energy metabolism52 and
protein translation23 and calcium signaling.53 To our knowledge,
no previous study has enriched for the PSD in bipolar disorder and
assessed its differential protein expression compared with
controls. Here, for we believe the ﬁrst time, we demonstrate the
importance of processes that underpin synaptic plasticity and
mitochondrial functions in the bipolar disorder PSD proteome.
The ﬁndings reported here are relevant to the previous
literature, implicating these processes in neuropsychiatric dis-
orders, in particular schizophrenia. Our team recently applied this
method to study the PSD in the ACC in schizophrenia and
observed altered expression of proteins involved in endocytosis,
long-term potentiation and calcium signaling.25 These ﬁndings are
consistent with previous gene and protein expression studies of
schizophrenia and, although to a lesser extent, bipolar disorder.49
Reduced expression of two proteins centrally involved in clathrin-
mediated endocytosis, namely Dynamin1 and AP2, were
described in the schizophrenia PSD. Interestingly, both these
proteins were found to be dysregulated in the current study,
arguing that the process of clathrin mediated endocytosis is
disturbed in major psychiatric disorder. The processes of long-
term potentiation and calcium signaling (see Table 2 and
Supplementary Table 6) were also implicated in the PSD in both
schizophrenia and the current study of bipolar disorder. This is in
keeping with previous studies and a shared role of these
processes in N-methyl-D-aspartate receptor function and synaptic
plasticity.51 We previously observed altered expression of proteins
with known roles in N-methyl-D-aspartate function, and in the
current study we have observed signiﬁcant downregulation of
ARFGAP, PLP1, SHANK3, CAMK2B, SYNPO and PRDX1 and
upregulation of AMPH. The mitochondrial-related proteins
(ATP5H, SSBP1, SLC25A4 and NDUFV2) previously shown to be
differentially expressed in the PSD in schizophrenia were also
differentially expressed in the PSD in bipolar disorder.
Beyond our hypothesized ﬁndings, we observed highly
signiﬁcant upregulation for each Septin 3, 5, 7, 8, 9 and 11.
Septins have roles in dendritic spine morphology,54 myelination,55
synaptic vescicle fusion,56 membrane curvature57 and cytoskeletal
dynamics, which has been implicated in schizophrenia.58 Septin 5,
6 and 11 speciﬁcally have been implicated in schizophrenia and
bipolar disorder previously in keeping with the proposed
synaptic–dendritic basis to the disorders.59
It is informative to place the differentially expressed bipolar
disorder proteome reported here with current genomic literature.
First, there is a 42% overlap between our study and a highly
enriched functionally related PSD gene set reported in an
integrative genomic study in bipolar disorder brain samples
(17/40 proteins)14 (see Supplementary Table 7 for details of these
ﬁndings).
Second, three of our differentially expressed proteins over-
lapped with the nine genes that were reported in a pathway meta-
analysis of bipolar disorder and showed differential expression in
the dorsolateral prefrontal cortex in bipolar disorder patients:48
inositol 1,4,5-trisphosphate receptor type 1 (Po0.005, overlap
with ITPR2 isoform of 65% as determined by BLAST analysis),
dystrobrevin alpha (DTNA, Po0.05) and neurotrophic tyrosine
kinase receptor.
Third, Konradi et al.29 identiﬁed 43 genes altered at the mRNA
level in the hippocampus in bipolar disorder patients. We have
shown that 56% of those were also dysregulated in our
differentially expressed bipolar disorder proteome reported here
(see Supplementary Table 8 for details). Furthermore, the PSD is
implicated with schizophrenia through several genome-wide
association and whole-exome-sequencing studies. However,
genome-wide association studies and pathway analysis of
genome-wide association studies data from the Psychiatric
Genomics Consortium have not identiﬁed PSD-associated genes
in their primary ﬁndings as contributing to bipolar disorder risk.
The lack of ﬁndings may be because of sample size differences
between schizophrenia and bipolar disorder genome-wide
association studies, and we wait with anticipation for the next
installment from the Psychiatric Genetics Disorder on Bipolar
Disorder, promising samples of 420 000 cases. Studies to date
have implicated histone methylation,21 cAMP signaling,22 nuclear
mitochondrial genes,48 although there is mounting evidence for
mitochondrial DNA variants in schizophrenia,60 and to a lesser
degree in bipolar disorder. More robust evidence, which would
have an impact on mitochondrial function, is derived from genetic
studies pointing to the involvement of the calcium channels in
bipolar disorder, and studies of peripheral cells from subjects with
bipolar disorder have shown alteration in calcium dynamics and
energy production.61 Energy production is a function of mito-
chondria, and thus these changes are consistent with the
current study.
The most robust ﬁnding in the current study is the upregulation
of proteins with roles in mitochondrial function. While evidence
from many studies implicates mitochondrial function in bipolar
disorder, and indeed schizophrenia (for review see Konradi
et al.30), the degree to which mitochondrial-associated proteins
were dysregulated in the current study is more marked than that
observed previously in the same Stanley series of brains (using
unenriched material). This suggests that the mitochondrial-
associated protein expression is most marked in the PSD fraction,
a ﬁnding that may shed light on the ﬁndings of several
transcriptomic studies, which did not demonstrate prominent
alteration in mitochondrial-associated genes.62 Mitochondria are
anatomically closely associated with synapses and are essential for
the ATP generation, which in turn underpins the protein
phosphorylation reactions that mediate synaptic signaling
through calcium regulation, exocytosis, vesicle recruitment,
Proteomic analysis of the PSD in BPD
M Föcking et al
6
Translational Psychiatry (2016), 1 – 9
potentiation of neurotransmitter release and synaptic plasticity.23
As the provision of an ATP supply power synapse-associated
polyribosome complexes and clathrin-dependent endocytic
machinery at postsynaptic sites, our observations of altered EIF2
signaling and endocytosis in the PSD in bipolar disorder could
potentially be secondary to altered mitochondrial function. EIF2
signaling has been observed recently in two studies of
schizophrenia-derived stem cells,63,64 thus implicating the process
of protein translation in both of the major psychosis. The ﬁndings
raise the testable hypothesis that the major psychoses involve
altered mitochondrial function at the level of the synapse that has
an impact locally on protein translation and endocytosis, and so
on altered synaptic plasticity. Altered trafﬁcking patterns of
mitochondria to postsynaptic densities may also contribute, and
this possibility is supported by the observed altered expression in
the current study of mitochondrial-trafﬁcking proteins KIF1A,
DynLL2 and the clathrin mediated endocytosis-associated protein
Dynamin1. Further studies are warranted for a deeper under-
standing of the mitochondrial proteins, and to test whether the
mitochondrial changes are indeed primary, and the synaptic
changes secondary, as there also is the possibility that this could
be the opposite.
Our study has several strengths and weaknesses. We used
proteomic technology to identify differentially expressed proteins
within the PSD in bipolar disorder. With more sensitive mass
spectrometers being developed, the differences and the amount
of identiﬁcations have been improved. Whereas our previous set
of schizophrenia PSD samples were run on a linear ion trap (LTQ
Orbitrap (at the end of 2012)), for the current study we used a
quadrupole mass ﬁlter (Q-Exactive). We conﬁrmed the protein
expression changes of a number of proteins that were broadly
representative of the main implicated functional pathways and
processes using western blotting. We conﬁrmed altered expres-
sion of proteins involved in clathrin mediated endocytosis, such as
Dynamin1, Dystrobrevin (involved in the formation and stability of
synapses), and the mitochondrial proteins NDUFV2 and SSBP;
while NDUFV2 is involved in electron transfer, SSBP1 is involved in
mitochondrial biogenesis and also conﬁrmed Septin 11.
A further strength of our ﬁndings is the consistency of the
direction of changes of proteins involved in several of the
implicated pathways and processes. For example, 38 of the 39
mitochondria-associated proteins as shown by Ingenuity Pathway
Analysis to be dysregulated in BPD were increased.
Postmortem studies have limitations that include the well-
known confounds such as chronic exposure to neuroleptics,
alcohol, tissue pH and postmortem delay that can confound these
studies. We designed our study so that age, brain pH and sex were
matched closely across groups. We could not account for the
potential inﬂuence of medication effects, alcohol use, smoking or
other recreational substance use, and future work will be needed
to address these issues. In particular, it is known that antidepres-
sants and smoking have effect on mitochondrial functions;50,65
however, the direction of these inﬂuences is inconclusive.66,67
In order to account for the potential effect of chronic
exposure to neuroleptics in our bipolar disorder cases, we studied
the PSD proteome of rats chronically exposed to haloperidol. Few
changes were identiﬁed following this treatment, although four
proteins—FAM163A, RIN1, mTOR and MCCC1—shown to be
dysregulated in bipolar disorder were dysregulated in the same
direction by haloperidol treatment, suggesting that these effects
may have been drug treatment-related (see Supplementary Table
9). We also compared our ﬁndings with data from recently
published articles of chronic treatment of rats with lithium or
valproate.68–70 Nanavati et al.69 used proteomic methods to assess
the PSD-enriched hippocampus following chronic treatment with
lithium or valproate. Overall, there was little overlap with our
ﬁndings, although they did observe dysregulation of ANK3, IGSF8
and CAPZB in the same direction as observed by us, suggesting
that their ﬁndings may be drug treatment-related. Two other
proteomic studies of the rat prefrontal cortex following chronic
lithium or valproate treatment identiﬁed CNP, GAP43, MAP2,
MAPRE2 and TCEB2 in the same direction as in the bipolar data
set, indicating that these ﬁndings may be drug treatment-related
(see Supplementary Table 9). However, we cannot fully conﬁrm or
exclude correlations within the patient group between the key
proteins and medication as for this we would have to look at drug-
naive patient samples that were not available to us. Previous
studies are supportive of the view that mitochondrial hypofunc-
tion may be induced by antipsychotic agents, although dendritic
morphology71 and mitochondrial gene expression27 are reported
to be unchanged or largely reduced72 and mood stabilizers are
considered to have a neuroprotective effect on mitochondria.30 It
should also be appreciated that our understanding of the broader
protein content of the PSD is based on proteomic studies of
enriched samples and that the methods used can vary, leading to
different PSD proteomes. The method used is seen as enrichment
rather than a fractionation technique, and there is a possibility
that the mitochondrial proteins in the PSD-enriched fraction might
come from other cellular locations.
However, our PSD enrichment method is well published, and
this along with our sensitive LC-MS/MS method yielded a PSD
proteome, which is very similar to that described previously.
In conclusion, in this study, which is to our knowledge the ﬁrst
of its kind, we have identiﬁed and compared the unique set of
proteins involved in the PSD in bipolar disorder. Our study
provides unique insights into the disorder at the synaptic level
and suggests that mechanisms involving altered mitochondrial
function, protein translation, calcium signaling, endocytosis and
septin function at the level of the PSD are involved in the
pathophysiology of bipolar disorder. As these processes act in
concert to support synaptic plasticity, they provide insights into
the variety of processes that may be targeted in the search for
novel treatments for the disorder.
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